Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient:A randomised,double-blind,placebo-controlled study

作     者：Panot Sainamthip Chutcharn Kongphanich Naiyarat Prasongsook Sakkarin Chirapongsathorn 

作者机构：Department of PharmacologyChulalongkorn UniversityBangkok 10330Thailand Department of RadiologyPhramongkutklao College of MedicineBangkok 10400Thailand Division of Medical OncologyDepartment of MedicinePhramongkutklao College of MedicineBangkok 10400Thailand Division of Gastroenterology and HepatologyDepartment of MedicinePhramongkutklao College of MedicineJatujak 10900Thailand 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2021年第9卷第30期

页      面：9059-9069页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital Mahidol University for English Language Editing Office of Research and Development Phramongkutklao College of Medicine 

主　　题：Hepatocellular carcinoma Chemoembolization Dexamethasone Double blind method Prevention Postembolization syndrome 

摘      要：BACKGROUND Even in the immuno-oncology era,transcatheter arterial chemoembolisation(TACE)is the most effective way to treat intermediate stage hepatocellular carcinoma(HCC).Postembolisation syndrome(PES)is the most common side effect from TACE and there is still no standard prevention *** To evaluate the efficacy of single dose intravenous dexamethasone regimen to prevent PES after TACE among patients with *** This study enrolled patients with HCC who had eligible indication for TACE without macrovascular invasion/extrahepatic *** were randomly assigned to either an intravenous single dose of dexamethasone 8 mg or placebo one hour before *** primary outcome was a negative result of PES at 48 h after TACE,which was defined as score2 of Southwest Oncology Group toxicity coding criteria using fever,nausea,vomiting and pain to *** the secondary end point was duration of admission between two *** One hundred patients were randomly assigned 1:*** intention-to-treat analysis,49 patients were randomly assigned to the dexamethasone and 51 to the placebo *** groups were similar for baseline *** negative PES rate was significantly higher in the dexamethasone group than in the placebo group(63.3%vs 29.4%;P=0.005).Mean Southwest Oncology Group toxicity coding PES was 2.14(95%CI:1.41-2.8)vs 3.71(95%CI:2.97-4.45)between the dexamethasone and placebo groups,*** incidence of fever was significantly lower in dexamethasone group with P0.001,pain,nausea and vomiting were also lower in the dexamethasone group compared with the placebo group(P=0.16,P=0.11,and P=0.49).The dexamethasone regimen was generally well tolerated by patients with HCC patients including those with hepatitis B virus infection and well-controlled diabetes *** Single dose dexamethasone was effective at preventing PES among patients with HCC treated with *** study showed no adverse events